Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
AuthorVaughn, Byron P
Yarur, Andres J
Campbell, James P
Lee, Jennifer Y
Osterman, Mark T
Cheifetz, Adam S
Cross, Raymond K
JournalJournal of Clinical Medicine
MetadataShow full item record
AbstractSerum vedolizumab concentrations are associated with clinical response although, it is unknown if vedolizumab concentrations predict response to dose escalation. The aim of this study was to identify if vedolizumab trough concentrations predicted the response to vedolizumab dose escalation. We assessed a retrospective cohort of patients on maintenance vedolizumab dosing at five tertiary care centers with vedolizumab trough concentrations. Multivariate logistic regression was used to control for potential confounders of association of vedolizumab concentration and clinical status. Those who underwent a dose escalation were further examined to assess if vedolizumab trough concentration predicted the subsequent response. One hundred ninety-two patients were included. On multivariate analysis, vedolizumab trough concentration (p = 0.03) and the use of immunomodulator (p = 0.006) were associated with clinical remission. Receiver operator curve analysis identified a cut off of 7.4 μg/mL for clinical remission. Of the fifty-eight patients with dose escalated, 74% of those with a vedolizumab concentration <7.4 μg/mL responded versus 52% of those with a vedolizumab trough concentration ≥7.4 μg/mL (p = 0.08). After adjustment for relevant confounders, the odds ratio for response with vedolizumab concentration <7.4 μg/mL was 3.7 (95% CI, 1.1-13; p = 0.04). Vedolizumab trough concentration are associated with clinical status and can identify individuals likely to respond to dose escalation. However, a substantial portion of patients above the identified cut off still had a positive response. Vedolizumab trough concentration is a potentially helpful factor in determining the need for dose escalation in patients losing response.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16617
- Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
- Authors: Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ
- Issue date: 2019 Oct
- Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
- Authors: Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, Noman M, Van Assche G, Ferrante M, Gils A, Vermeire S
- Issue date: 2018 Dec
- Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
- Authors: Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X
- Issue date: 2017 Nov
- Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.
- Authors: Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L
- Issue date: 2019 Aug 14
- Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
- Authors: Yacoub W, Williet N, Pouillon L, Di-Bernado T, De Carvalho Bittencourt M, Nancey S, Lopez A, Paul S, Zallot C, Roblin X, Peyrin-Biroulet L
- Issue date: 2018 Apr